The Evaluation of Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
Authors:
- Sinan MersinSMSinan Mersin
- Ayfer GedükAGAyfer Gedük
- Özgür MehtapÖMÖzgür Mehtap
- Pınar TarkunPTPınar Tarkun
- Serkan ÜnalSÜSerkan Ünal
- Merve Gökçen PolatMPMerve Gökçen Polat
- Kemal AygünKAKemal Aygün
- Emel Merve YenihayatEYEmel Merve Yenihayat
- Hayrunnisa AlbayrakHAHayrunnisa Albayrak
- Abdullah HacıhanifioğluAHAbdullah Hacıhanifioğlu
Open Access
- 4 May 2021
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 38 (3) , 211-217
Abstract
Constantly increasing health expenditures lead use of generic molecules and generics of bortezomib have been used for a long time. The aim of this study is to retrospectively examine the effectiveness, side effects and reliability of generic bortezomib in newly diagnosed multiple myeloma (MM) patients. The data of 95 patients who received four cycles of bortezomib as a first- or second-line therapy in a single center were retrospectively recorded. Treatment responses, side effects and progression free survival (PFS) rates have been calculated and compared. Of the 95 patients, 42 used the original and 53 used the generic molecule. Epidemiological data, MM types, genetic risk groups, laboratory values at diagnosis and bortezomib treatment lines (as a first line or second) were evaluated, and there was no statistical difference between the two groups. When the response rates were evaluated with International Myeloma Working Group (IMWG) criteria, there were no significant difference (p: 0,42). Partial response (PR) and above response rates were similar (%81 vs %79,2 p:0,836). PFS values were 42.8 months in the original and 37.8 months in the generic molecule group (p: 0,68). Side effects were seen in 44,2% of patients, and the most common side effects were neuropathy, cytopenias and infections. They were similar in both groups (p: 0,67). Although this retrospective study is limited, it is the first study comparing the original molecule of bortezomib with its generic. There was no statistical difference between the two groups in terms of treatment responses, PFS times and side effects. However, large-scale evaluations can help obtain healthier data on this subject.Keywords
This publication has 22 references indexed in Scilit:
- Safety and efficacy of generic drugs with respect to brand formulationJournal of Pharmacology and Pharmacotherapeutics, 2013
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaBritish Journal of Haematology, 2011
- The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)Haematologica, 2007
- Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myelomaBritish Journal of Haematology, 2007
- Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell LeukemiaJapanese Journal of Clinical Oncology, 2007
- Do generics offer significant savings to the UK National Health Service?Current Medical Research and Opinion, 2006
- Bortezomib (Velcade?) in the treatment of multiple myelomaTherapeutics and Clinical Risk Management, 2006
- Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignanciesCancer Treatment Reviews, 2005
- Generic Low-Molecular-Weight Heparins: Some Practical ConsiderationsSeminars in Thrombosis and Hemostasis, 2004
- The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugsClinical Therapeutics, 2003